The Orthopedic Biomaterial Market, estimated at USD 20.87 Bn in 2026, is expected to exhibit a CAGR of 10.1% and reach USD 40.94 Bn by 2033.
The industry is witnessing significant growth driven by rising demand for advanced, reliable, and cost-effective medical devices across diagnostic, therapeutic, and monitoring applications. Rapid advancements in device design, digital health integration, and adoption of minimally invasive technologies are reshaping the competitive landscape. Furthermore, supportive regulatory frameworks, increasing healthcare investments, and the growing focus on patient-centric care are expected to create new growth avenues for market players.
Market players are engaged in getting product approvals from regulatory authorities, and this is expected to drive the global orthopedic biomaterial market growth. For instance, in August 2023, RevBio, Inc., a clinical-stage medical device company, announced that it had received U.S. Food and Drug Administration (FDA) approval to begin a 20-patient clinical trial to investigate the safety and efficacy of a more rapidly replaced, pH-modified porous formulation of the company's bone adhesive biomaterial known as Tetranite to immediately stabilize dental implants following tooth extractions. This new formulation appears to have a more physiologically active bone replacement. While not osteoinductive, this patent-pending form of tetranite has demonstrated "osteopromotive" properties.
Global Orthopedic Biomaterial Market: Key Developments
- In June 2026, Advita Ortho announced the first clinical use of its next-generation knee replacement platform in Japan. The system integrates Activit-E vitamin E-stabilized polyethylene in the Truliant knee system with Advita GPS surgical navigation and Newton balancing intelligence. Initial procedures were performed by Dr. Hiroshi Watanabe at Tokorozawa Hakushokai Hospital, supporting real-time alignment, balance assessment, and personalized total knee replacement workflows for improved surgical decision-making and patient care outcomes.
- In March 2026, SINTX Technologies announced the first-in-human surgery using its FDA-cleared SINAPTIC Foot & Ankle Osteotomy Wedge System, marking its entry into foot and ankle reconstruction. The procedure was performed on March 13, 2026, by Dr. Scott Carrington at Emplify Health in Wisconsin. The silicon nitride implant is designed to support bone integration, reduce bacterial adhesion, and improve imaging visibility, advancing SINTX’s broader orthopedic commercialization and U.S. launch strategy.
- In April 2026, Regentis Biomaterials announced a collaboration with Humanitas Research Hospital in Milan to support European deployment of GelrinC, its CE Mark-approved hydrogel implant for knee cartilage repair. Prof. Elizaveta Kon will help lead Regentis’ Centers of Excellence network, advancing surgeon education, clinical guidance, and responsible adoption. GelrinC offers an off-the-shelf, cell-free, 10-minute procedure designed to regenerate cartilage and improve patient recovery outcomes across Europe for active patients clinically.
- In January 2026, Spineology, physiotherapy center launched OptiMesh HA Nano, a conforming patient-specific expandable interbody implant for advanced lumbar spinal fusion. The platform combines Spineology’s OptiMesh expandable implant technology with Promimic’s patented HA Nano hydroxyapatite surface treatment. Designed to support cellular interaction, osseointegration, and bioactive bone-implant bonding, the innovation aims to enhance fusion outcomes while maintaining structural stability, FDA clearance requirements, and minimally invasive, anatomy-adaptive spinal care.
- In April 2026, researchers from CU Boulder, CU Anschutz, and Colorado State University reported promising regenerative therapies for osteoarthritis. Supported by ARPA-H’s NITRO program, the team developed a single joint injection and biomaterial repair kit that encouraged damaged joints to heal in animal studies. Treated joints returned to healthy condition within four to eight weeks, while the project advanced to its next phase toward clinical trials in humans and commercialization. (Source: CU Boulder)
Browse 26 Market Data Tables and 29 Figures spread through 180 Pages and in-depth TOC on “Global Orthopedic Biomaterial Market”- Forecast to 2033, Global Orthopedic Biomaterial Market, By Material Type (Glass-ceramic & Bioactive Glasses, Calcium Phosphate Cements, Polymer, Metals, and Composites), By Application (Joint Replacement, Spine Implants, Orthobiologics, Viscosupplementation, Bio-resorbable Tissue Fixation, and Others), By End User (Hospitals, Orthopedic Clinics, and Others), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)
To know the latest trends and insights prevalent in this market, click the link below:
https://www.coherentmarketinsights.com/market-insight/orthopedic-biomaterial-market-4474
Key Takeaways of the Global Orthopedic Biomaterial Market
- The global orthopedic biomaterials market is expected to exhibit a CAGR of 10.1% during the forecast period. The merger with emerging economies offers lucrative growth opportunities for players in the global orthopedic biomaterial market.
- Among application, the joint replacement segment is expected to hold a dominant position in the global orthopedic biomaterial market during the forecast period. The large market share for joint replacement biomaterials can be attributed to the rising cases of osteoarthritis and musculoskeletal disorders globally. For instance, according to the World Health Organization (WHO), in July 2023, about 528 million people worldwide were living with osteoarthritis in 2019. About 73% of people living with osteoarthritis are older than 55 years, and 60% are female. . As the geriatric population increases, the demand for joint replacement procedures utilizing orthopedic biomaterials is expected to rise.
- Among regions, North America is expected to be the dominant region in the global orthopedic biomaterial market owing to increasing product approvals by regulatory authorities in the region. For instance, in October 2020, Northwestern University and the Regenerative Engineering Society (RES), a non-profit organization based in the U.S., announced that their novel material is the first thermoset biodegradable synthetic polymer to be approved by the U.S. Food and Drug Administration (FDA) for use in an implantable medical device. The device was designed to connect soft tissue grafts to bone during operations. This authorized biomaterial, known as CITREGEN, aids in the healing of transplanted tissues by recreating their natural biochemical and structural support network.
- The major players operating in the global orthopedic Biomaterial Market are B. Braun Melsungen AG, CONMED Corp., Evonik Industries AG, Medtronic Plc., Smith & Nephew Plc., Stryker Corp., Victrex Plc. (Invibio Ltd.), and Zimmer Biomet Holdings Inc., Globus Medical, Heraeus Holding GmbH, Exactech Inc., Collagen Matrix Inc., Koninklijke DSM N.V., DePuy Synthes.
Contact Us